Cargando…
Iranian clinical practice guideline for amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegeneration involving motor neurons. The 3–5 years that patients have to live is marked by day-to-day loss of motor and sometimes cognitive abilities. Enormous amounts of healthcare services and resources are necessary to support pat...
Autores principales: | Boostani, Reza, Olfati, Nahid, Shamshiri, Hosein, Salimi, Zanireh, Fatehi, Farzad, Hedjazi, Seyed Arya, Fakharian, Atefeh, Ghasemi, Majid, Okhovat, Ali Asghar, Basiri, Keivan, Haghi Ashtiani, Bahram, Ansari, Behnaz, Raissi, Gholam Reza, Khatoonabadi, Seyed Ahmadreza, Sarraf, Payam, Movahed, Sara, Panahi, Akram, Ziaadini, Bentolhoda, Yazdchi, Mohammad, Bakhtiyari, Jalal, Nafissi, Shahriar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272856/ https://www.ncbi.nlm.nih.gov/pubmed/37333000 http://dx.doi.org/10.3389/fneur.2023.1154579 |
Ejemplares similares
-
Guillain-Barre Syndrome and COVID-19 Vaccine: A Report of Nine Patients
por: Karimi, Narges, et al.
Publicado: (2021) -
Myasthenia gravis associated with novel coronavirus 2019 infection: A report of three cases
por: Karimi, Narges, et al.
Publicado: (2021) -
A retrospective study of the safety and efficacy of rituximab in Iranian patients with myasthenia gravis: A single-center experience
por: Ziaadini, Bentolhoda, et al.
Publicado: (2022) -
Guillain-Barre syndrome in patients with coronavirus disease-2019: Report of six cases and review of literature
por: Okhovat, Ali Asghar, et al.
Publicado: (2020) -
Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar
por: Fatehi, Farzad, et al.
Publicado: (2021)